$599

Madrigal Submits Resmetirom NASH NDA

Madrigal Pharmaceuticals announced it initiated a rolling submission with FDA for an NDA seeking accelerated approval for resmetirom for the treatment of NASH with liver fibrosis. According to the press release, Madrigal has submitted the majority of the NDA to FDA and plans to submit the remaining components in July 2023 along with a request for priority review. For context, in April 2023, resmetirom received Breakthrough Therapy designation for the treatment of NASH with liver fibrosis (previous FENIX insight). Recall, on June 22, 2023, Madrigal announced new MAESTRO-NASH data at EASL 2023 (previous FENIX insight).

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.